Research Analysts Issue Forecasts for TSE:GUD Q2 Earnings

Knight Therapeutics Inc. (TSE:GUD) – Stock analysts at Stifel Canada issued their Q2 2025 earnings per share estimates for Knight Therapeutics in a research note issued on Monday, March 24th. Stifel Canada analyst J. Keywood expects that the company will post earnings of $0.04 per share for the quarter. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Stifel Canada also issued estimates for Knight Therapeutics’ FY2025 earnings at $0.17 EPS.

Other equities analysts have also recently issued reports about the company. Canaccord Genuity Group cut Knight Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, March 21st. Research Capitl raised shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, March 11th. Finally, Stifel Nicolaus raised their price objective on shares of Knight Therapeutics from C$6.25 to C$7.45 and gave the stock a “buy” rating in a report on Tuesday. One investment analyst has rated the stock with a hold rating, one has issued a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of C$7.48.

Knight Therapeutics Price Performance

Shares of TSE GUD opened at C$6.00 on Wednesday. The company has a quick ratio of 1.79, a current ratio of 3.36 and a debt-to-equity ratio of 7.52. Knight Therapeutics has a fifty-two week low of C$5.09 and a fifty-two week high of C$6.45. The business has a 50 day moving average price of C$5.73 and a two-hundred day moving average price of C$5.59. The firm has a market cap of C$606.90 million, a PE ratio of -20.03, a price-to-earnings-growth ratio of -1,013.50 and a beta of 0.50.

Insiders Place Their Bets

In other news, insider Sime Armoyan sold 2,500,000 shares of the business’s stock in a transaction that occurred on Friday, March 21st. The stock was sold at an average price of C$6.30, for a total value of C$15,750,000.00. Insiders have sold a total of 3,143,300 shares of company stock valued at $19,733,740 in the last quarter. Insiders own 45.62% of the company’s stock.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.